The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Overcoming challenges in R/R MCL: promising combinations & treatment options being explored
David Lewis, MD, Plymouth University, Plymouth, UK, comments on the changing treatment landscape in relapsed/refractory (R/R) mantle cell lymphoma (MCL), highlighting that certain groups of patients, such as those with blastoid disease, TP53 mutations, and short duration of response to first-line treatment, are at high risk of poor outcomes. Dr Lewis suggests that CAR T-cell therapy, BTK inhibitor-based combinations, and bispecific antibodies may offer new treatment options for these patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
